Journal of Pharmacokinetics and Biopharmaceutics

, Volume 19, Issue 5, pp 537–552 | Cite as

A kinetic-dynamic model to explain the relationship between high potency and slow onset time for neuromuscular blocking drugs

  • FranÇois Donati
  • Claude Meistelman


To account for experimental data showing increased onset time with increased potency of neuromuscular blocking drugs, a pharmacokinetic-pharmacodynamic model is presented. It is characterized by a finite concentration of receptors (R)in the effect compartment. Transfer from central to effect compartment is linearly related to concentration gradient. A sigmoid Emaxmodel is used to describe the relationship between receptor occupancy and effect. Plasma concentrations found in the literature are used. Differential equations are solved numerically for equipotent doses of drugs of different potencies. Because the density of receptors constitutes a significant drain of drug molecules for potent drugs, the model predicts an inverse relationship between speed of onset and potency. The concentration of receptors in the effect compartment Rwhich best fits experimental data obtained in humans is 0.28 Μmol/L. With this value of R,onset times are prolonged when the ED95(dose for 95% blockade) is less than 0.1 Μmol/kg. It is concluded that, in the development of a short-acting nondepolarizing neuromuscular blocking drug, agents having an ED95of 0.1 Μmol/kg or greater appear more promising.

Key words

Modeling neuromuscular blocking drugs pharmacodynamics pharmacokinetics potency onset time 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W. C. Bowman, I. W. Rodger, J. Houston, R. J. Marshall, and I. McIndewar. Structure: action relationships among some deacetoxy analogues of pancuronium and vecuronium in the anesthetized cat.Anesthesiology 69:57–62 (1988).PubMedCrossRefGoogle Scholar
  2. 2.
    A. F. Kopman. Pancuronium, gallamine, and d-tubocurarine compared: Is speed of onset inversely related to drug potency?Anesthesiology 70:915–920 (1989).PubMedCrossRefGoogle Scholar
  3. 3.
    W. D. M. Paton and D. R. Waud. The margin of safety of neuromuscular transmission.J. Physiol 191:59–90 (1967).PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    F. Donati. Onset of action of relaxants.Can. J. Anaesth. 35:S52-S58 (1988).PubMedCrossRefGoogle Scholar
  5. 5.
    L. B. Sheiner, D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. Simultaneous modeling of pharmacokinetics and pharmacodynamics: Application to d-tubocurarine.Clin. Pharmacol. Ther. 25:358–371 (1979).PubMedGoogle Scholar
  6. 6.
    E. Fuseau and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.Clin. Pharmacol. Ther. 35:733–741 (1984).PubMedCrossRefGoogle Scholar
  7. 7.
    J. D. Unadkat, F. Bartha. and L. B. Sheiner. Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.Clin. Pharmacol. Ther. 40:86–93 (1986).PubMedCrossRefGoogle Scholar
  8. 8.
    W. A. Colburn. Simultaneous pharmacodynamic and pharmacokinetic modeling.J. Pharmacokin. Biopharm. 9:367–388 (1981).CrossRefGoogle Scholar
  9. 9.
    N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models.Clin. Pharmacokin. 6:429–453 (1981).CrossRefGoogle Scholar
  10. 10.
    C. A. Shanks. Pharmacokinetics of nondepolarizing muscle relaxants applied to calculation of bolus and infusion dosage regimens.Anesthesiology 64:72–86 (1986).PubMedCrossRefGoogle Scholar
  11. 11.
    S. Ward, N. Boheimer, B. C. Weatherley, R. J. Simmonds, and T. A. Dopson. Pharmacokinetics of atracurium and its metabolites in patients with renal function, and in patients with renal failure.Br. J. Anaesth. 59:697–706, 1987.PubMedCrossRefGoogle Scholar
  12. 12.
    F. M. deBros, A. Lai, R. Scott, J. deBros, A. G. Batson, N. Goudsouzian, H. H. Ali, A. B. Cosimi, and J. J. Savarese. Pharmacokinetics and pharmacodynamics of atracurium during isoflurane anesthesia in normal and anephric patients.Anesth. Analg. 65:743–746 (1986).PubMedCrossRefGoogle Scholar
  13. 13.
    Y. J. Sohn, A. F. Bencini, A. H. J. Scaf, U. W. Kersten, and S. Agoston. Comparative pharmacokinetics and dynamics of vecuronium and pancuronium in anesthetized patients.Anesth. Analg. 65:233–239 (1986).PubMedCrossRefGoogle Scholar
  14. 14.
    A. F. Bencini, A. H. J. Scaf, Y. J. Sohn, C. Meistelman, A. Lienhart, U. W. Kersten, S. Schwarz, and S. Agoston. Disposition and urinary excretion of vecuronium bromide in anesthetized patients with normal renal function or renal failure.Anesth. Analg. 65:245–251 (1986).PubMedCrossRefGoogle Scholar
  15. 15.
    R. S. Matteo, K. Nishitateno, E. K. Pua, and S. Spector. Pharmacokinetics of d-tubocurarine in man: Effect of an osmotic diuretic on urinary excretion.Anesthesiology 52:335–338 (1980).PubMedCrossRefGoogle Scholar
  16. 16.
    R. S. Matteo, W. W. Backus, D. D. McDaniel, W. P. Brotherton, R. Abraham, and J. Diaz. Pharmacokinetics and pharmacodynamics of d-tubocurarine and metocurine in the elderly.Anesth. Analg. 64:23–29 (1985).PubMedGoogle Scholar
  17. 17.
    B. N. Swerdlow and F. O. Holley. Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships.Clin. Pharmacokin. 12:79–110 (1987).CrossRefGoogle Scholar
  18. 18.
    D. J. Murray, M. P. Mehta, W. W. Choi, R. B. Forbes, M. D. Sokoll, S. D. Gergis, G. D. Rudd, and M. M. Abou-Donia. The neuromuscular blocking and cardiovascular effects of doxacurium chloride in patients receiving nitrous oxide narcotic anesthesia.Anesthesiology 69:472–477 (1988).PubMedCrossRefGoogle Scholar
  19. 19.
    S. J. Basta, J. J. Savarese, H. H. Ali, P. B. Embree, A. F. Schwarz, G. D. Rudd, and W. B. Wastila. Clinical pharmacology of doxacurium chloride. A new long-acting non depolarizing muscle relaxant.Anesthesiology 69:478–486 (1988).PubMedCrossRefGoogle Scholar
  20. 20.
    D. L. Dresner, S. J. Basta, H. H. Ali, A. F. Schwartz, P. A. Embree, W. A. Wargin, A. A. Lai, K. A. Brady, and J. J. Savarese. Pharmacokinetics and pharmacodynamics of doxacurium in young and elderly patients during isoflurane anesthesia.Anesth. Analg. 71:498–502 (1990).PubMedCrossRefGoogle Scholar
  21. 21.
    R. P. F. Scott and J. Norman. Doxacurium chloride: A preliminary clinical trial.Br. J. Anaesth. 62:373–377 (1989).PubMedCrossRefGoogle Scholar
  22. 22.
    N. Krieg, J. F. Crul, and L. H. D. J. Booij. Relative potency of ORG NC 45, pancuronium, alcuronium and tubocurarine in anaesthetized man.Br. J. Anaesth. 52:783–788 (1980).PubMedCrossRefGoogle Scholar
  23. 23.
    A. Williams, H. Gyasi, C. Melloni and D. R. Bevan. Clinical experience with ORG NC45 (norcuron) as the sole muscle relaxant.Can. Anaesth. Soc. J. 29:567–572 (1982).PubMedCrossRefGoogle Scholar
  24. 24.
    E. N. Robertson, L. H. D. J. Booij, R. J. Fragen, and J. F. Crul. Clinical comparison of atracurium and vecuronium (ORG NC 45).Br. J. Anaesth. 55:125–129 (1983).PubMedCrossRefGoogle Scholar
  25. 25.
    T. E. J. Healy, N. D. Pugh, B. Kay, T. Sivalingam, and H. V. Petts. Atracurium and vecuronium: effect of dose on the time of onset.Br. J. Anaesth. 58:620–624 (1986).PubMedCrossRefGoogle Scholar
  26. 26.
    R. K. Mirakhur, C. J. Ferres, R. S. J. Clarke, I. M. Ball, and J. W. Dundee. Clinical evaluation of ORG NC 45.Br. J. Anaesth. 55:119–124 (1983).PubMedCrossRefGoogle Scholar
  27. 27.
    K. Rørvik, P. Husby, L. Gramstad, J. S. Vamnes, L. Bitsch-Larsen, and M. E. Koller. Comparison of large dose of vecuronium with pancuronium for prolonged neuromuscular blockade.Br. J. Anaesth. 61:180–185 (1988).PubMedCrossRefGoogle Scholar
  28. 28.
    A. Bencini and D. E. F. Newton. Rate of onset of good intubating conditions, respiratory depression and hand muscle paralysis after vecuronium.Br. J. Anaesth. 56:959–965 (1984).PubMedCrossRefGoogle Scholar
  29. 29.
    B. Ginsberg, P. S. Glass, T. Quill, D. Shafron, and K. D. Ossey. Onset and duration of neuromuscular blockade following high-dose vecuronium administration.Anesthesiology 71:201–205 (1989).PubMedCrossRefGoogle Scholar
  30. 30.
    M. R. Fahey, R. B. Morris, R. D. Miller, Y. J. Sohn, R. Cronnelly, and P. Gencarelli. Clinical pharmacology of ORG NC45 (Norcuron-TM: A new nondepolarizing muscle relaxant.Anesthesiology 55:6–11 (1981).PubMedCrossRefGoogle Scholar
  31. 31.
    K. Peper, R. J. Bradley, and F. Dreyer. The acetylcholine receptor at the neuromuscular junction.Physiol. Rev. 62:1271–1340 (1982).PubMedGoogle Scholar
  32. 32.
    D. R. Bevan, J. C. Bevan, and F. Donati.Muscle Relaxants in Clinical Anesthesia, Year Book Medical Publishers, Chicago, 1988.Google Scholar
  33. 33.
    F. Donati, J. Lahoud, C. M. Walsh, P. A. Lavelle, and D. R. Bevan. Onset of pancuronium and d-tubocurarine with priming.Can. Anaesth. Soc. J. 33:571–577 (1986).PubMedCrossRefGoogle Scholar
  34. 34.
    N. J. N. Harper, E. G. Bradshaw, and T. E. J. Healy. Evoked electromyographic and mechanical responses of the adductor pollicis compared during onset of neuromuscular blockade by atracurium or alcuronium, and during antagonism by neostigmine.Br. J. Anaesth. 58:1278–1284 (1986).PubMedCrossRefGoogle Scholar
  35. 35.
    J. Minsaas and J. Stovner. Artery-to-muscle onset time for neuromuscular blocking drugs.Br. J. Anaesth. 52:403–407 (1980).PubMedCrossRefGoogle Scholar
  36. 36.
    J. M. K. H. Wierda, A. P. De Wit, K. Kuizenga, and S. Agoston. Clinical observations on the neuromuscular blocking action of ORG 9426, a new steroidal non-depolarizing agent.Br. J. Anaesth. 64:521–523 (1990).PubMedCrossRefGoogle Scholar
  37. 37.
    G. A. Harrison and F. Junius. The effect of circulation time on the neuromuscular action of suxamethonium.Anaesth. Intensive Care 1:33–40 (1972).PubMedGoogle Scholar
  38. 38.
    J. C. Scott, K. V. Ponganis, and D. R. Stanski. EEG quantitation of narcotic effect: The comparative pharmacodynamics of fentanyl and alfentanil.Anesthesiology 62: 234–241 (1985).PubMedCrossRefGoogle Scholar

Copyright information

© Plenum Publishing Corporation 1991

Authors and Affiliations

  • FranÇois Donati
    • 1
    • 2
  • Claude Meistelman
    • 2
  1. 1.Department of AnaesthesiaMcGill UniversityMontrealCanada
  2. 2.Service d'anesthésieInstitut Gustave-RoussyVillejuifFrance

Personalised recommendations